AUG 28, 2018 9:58 PM PDT

Combination Therapy for Advanced Melonoma

WRITTEN BY: Nouran Amin

Image: Cancer Research UK

According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with advanced melanoma; an aggressive skin cancer. The research examined the molecular actions of an immunotherapy drug pembrolizumab and the bacterial agent SD-101 (a pattern of nucleic acids imitating a bacterial infection) on their alteration of microenvironment enclosing a tumor. The alteration enabled the immune system to effectively increase its attack on cancer.

The immunotherapeutic drug, pembrolizumab, marketed under the brand name ‘Keytruda’, worked by inhibiting PD-1, which is a protein that exerts actions on the function of the immune system. Inhibiting PD-1 with pembrolizumab allowed the immune system cells to better recognize cancer. While Pembrolizumab is actually known for treating people with advanced or metastatic cancers, however, the majority of metastatic melanoma tumors resisted the effects of the drug. "We have found that the reason patients with metastatic melanoma do not initially respond to immunotherapy with an anti-PD-1 is that their immune system was not ready," explained Dr. Antoni Ribas, lead author, professor of medicine at UCLA’s David Geffen School of Medicine, and director UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program. "So we thought, 'What if we change that by injecting the therapeutic drug into the metastatic lesions and change the microenvironment of the cancer? It's like having a pile of wood but not having a match to light it. With this new approach, SD-101 is the match that starts the fire."

Image: NorthShore.org

Interestingly, scientists discovered that SD-101 not only orchestrates T cells to cancer cells but also ensures the microenvironment is appropriate for T cells; allowing them to eradicate cancer cells. "For all patients with advanced cancer, immunotherapy using PD-1 inhibitors has really changed the face of cancer treatment. Unfortunately, this therapy still only works in a subset of patients," says Dr. Deborah Wong, author of the study and oncologist at the Ronald Reagan UCLA Medical Center. "This particular combination has been especially gratifying because not only does the SD-101 therapy drug induce tumor shrinkage at the actual site where it's injected, but it's working in conjunction with pembrolizumab to shrink tumors outside of the ones we're directly injecting."

The following study highlights the urge for more research behind combination therapies especially since many cancer patients do not readily respond to immunotherapy and often experience a reoccurrence of tumors post-treatment.

"We are really starting to understand the science of how immunotherapies work in patients," explained Ribas. “By understanding that, we can find more ways to make that therapy more active. One way is by combining the therapy with another agent that can overcome the resistance that some cancers have to these therapies."

Watch the video below to learn more about Melanoma!

Source: University of California - Los Angeles Health Sciences, Cancer Discovery

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
NOV 01, 2021
Health & Medicine
How Our Understanding of Cellular Reprogramming May Redefine Transplant Medicine
NOV 01, 2021
How Our Understanding of Cellular Reprogramming May Redefine Transplant Medicine
Liver disease represents a significant public health concern and was diagnosed in roughly 4.5 million adults i ...
NOV 20, 2021
Neuroscience
Fear balance - the brain and body communicate to maintain fear within an adaptive range
NOV 20, 2021
Fear balance - the brain and body communicate to maintain fear within an adaptive range
We have all experienced the emotion of fear. Although what one individual might fear (e.g. rollercoasters or snakes), mi ...
DEC 13, 2021
Cancer
Mistletoe: Parasite, Symbol of Romance, or Cancer Treatment?
DEC 13, 2021
Mistletoe: Parasite, Symbol of Romance, or Cancer Treatment?
As we approach the winter season, decorative swigs of mistletoe are starting to make their holiday debut.  You may ...
DEC 11, 2021
Health & Medicine
Third Dose of Pfizer-BioNTech Vaccine Could Reduce Effects of Omicron
DEC 11, 2021
Third Dose of Pfizer-BioNTech Vaccine Could Reduce Effects of Omicron
Many mainstream media sources are reporting on a new press release from Pfizer that suggests that a third dose of the Pf ...
JAN 11, 2022
Cannabis Sciences
Cannabis Varieties Used in Research Vary Significantly from Consumer Varieties
JAN 11, 2022
Cannabis Varieties Used in Research Vary Significantly from Consumer Varieties
Until just days ago, the University of Mississippi (UM) monopolized the cannabis research industry. Through a contract e ...
JAN 18, 2022
Drug Discovery & Development
Identifying Oncostatin M (OSM): One Protein's Role in Severe Asthma
JAN 18, 2022
Identifying Oncostatin M (OSM): One Protein's Role in Severe Asthma
Asthma is a chronic condition that is characterized by difficulty breathing, coughing, and wheezing which is caused, in ...
Loading Comments...